Investigational New Drugs

, Volume 30, Issue 6, pp 2443–2449

Predictive factors for response to treatment in patients with advanced renal cell carcinoma

  • Carolina Muriel López
  • Emilio Esteban
  • Aurora Astudillo
  • Pablo Pardo
  • Jose Pablo Berros
  • Marta Izquierdo
  • Guillermo Crespo
  • Paula J. Fonseca
  • Miguel Sanmamed
  • Pablo Martínez-Camblor


Introduction The analysis of predictive factors of response may aid in predicting which patients with advanced renal cell carcinoma (RCC) would be good candidates for systemic treatments. Materials and methods The expression of several biomarkers was retrospectively analyzed using immunohistochemistry (IHC), as well as 2 analytical variables in 135 patients with advanced RCC treated with cytokines (CK) and/or new targeted drugs (NTD). Results 67 patients were treated solely with NTD and 68 with CK (23 also received NTD). Univariate analysis: HIF1α did not correlate significantly with response to these drugs. Overexpression of CAIX was associated with more responses (%) to NTD (64.7 vs. 21.1; p = 0.004) and CK (22.6 vs. 0; p = 0.038). PTEN demonstrated predictive value of response to sunitinib (70.8 vs. 34.1; p = 0.005). p21 was associated with a lower response to sunitinib (35.9 vs. 65.4; p = 0.025). Thrombocytosis was not significantly associated with response to NTD, although it was with CK (0 vs. 20; p = 0.017). Neutrophilia correlated with a lower response to NTD (29.6 vs. 57.5; p = 0.045), although not with CK. Multivariate analysis: Overexpression of CAIX was an independent predictor of significantly higher response to NTD and CK; OR = 8.773 (p < 0.001). Conclusions Our findings highlight the usefulness of CAIX in selecting patients with advanced RCC as candidates for systemic treatment. PTEN and p21 may be important in predicting response to sunitinib. Thrombocytosis and neutrophilia correlate well with response to CK and NTD, respectively.


Advanced renal cell carcinoma New targeted drugs Cytokines Predictive factors of treatment response Molecular markers 


  1. 1.
    Godley PA, Ataga KI (2000) Renal cell carcinoma. Curr Opin Oncol 12:260–264PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Murria T, Ward E, Samuels A, Tiwari RC (2005) Cancer statistics. Cancer J Clin 55:10–30CrossRefGoogle Scholar
  3. 3.
    McLaughlin JK, Lipworth L (2000) Epidemiologic aspects of renal cell cancer. Semin Oncol 27:115–123PubMedGoogle Scholar
  4. 4.
    Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics Cancer J Clin 50.Google Scholar
  5. 5.
    Vinels P, Alavanja M, Buffer P et al (2004) Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96:99–106CrossRefGoogle Scholar
  6. 6.
    Maclurem WW (1990) A case control study of diet and risk of renal adenocarcinoma. Epidemiology 1:430CrossRefGoogle Scholar
  7. 7.
    Hunt JD, van der Hel OL, McMillan GP et al (2005) Renal cell carcinoma en relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 114:101–108PubMedCrossRefGoogle Scholar
  8. 8.
    Bergstrom A, Hsich CC, Lindbland P et al (2001) Obesity and renal cell cancer: a quantitative review. Br J Cancer 85:984–990PubMedCrossRefGoogle Scholar
  9. 9.
    Bergstrom A, Pisani P, Tenet V et al (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91:421–430PubMedCrossRefGoogle Scholar
  10. 10.
    Calle EE, Kaasks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591PubMedCrossRefGoogle Scholar
  11. 11.
    Wolchok JD, Motzer RJ (2000) Management of renal cell carcinoma. Oncology 14:29–34PubMedGoogle Scholar
  12. 12.
    Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353:14–17CrossRefGoogle Scholar
  13. 13.
    Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132PubMedCrossRefGoogle Scholar
  14. 14.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRefGoogle Scholar
  15. 15.
    Escudier B, Szezylik C, Eisen T et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRefGoogle Scholar
  16. 16.
    Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRefGoogle Scholar
  17. 17.
    Escudier BJ, Bellmunt J, Negrier S et al (2009) Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:15s (suppl; abstr 5020)Google Scholar
  18. 18.
    Motzer RJ, Escudier B, Oudard S, RECORD-1. Study Group et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456PubMedCrossRefGoogle Scholar
  19. 19.
    Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068PubMedCrossRefGoogle Scholar
  20. 20.
    Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802–811PubMedGoogle Scholar
  21. 21.
    Hager M, Haufe H, Kemmerling R et al (2007) PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology 39:482–485PubMedCrossRefGoogle Scholar
  22. 22.
    Bozhurt SU, Avan E, Bolukbasi F et al (2009) Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS 117(9):651–659CrossRefGoogle Scholar
  23. 23.
    Zoblec I, Steele R, Terracciano L et al (2007) Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60(10):1112–1116CrossRefGoogle Scholar
  24. 24.
    Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32–35PubMedCrossRefGoogle Scholar
  25. 25.
    Miller AB, Hooqstraten B, Staquet M et al (1958) Reporting results of cancer treatment. Cancer 47:207–214CrossRefGoogle Scholar
  26. 26.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  27. 27.
    Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic factors stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540PubMedGoogle Scholar
  28. 28.
    Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:286–296Google Scholar
  29. 29.
    Mekhail TM, Abou-Jawde RM, BouMerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832–841PubMedCrossRefGoogle Scholar
  30. 30.
    Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 is a negative factor for tumor therapy. Oncogene 22:3213–3220PubMedCrossRefGoogle Scholar
  31. 31.
    Brugarolas J (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356:185–187PubMedCrossRefGoogle Scholar
  32. 32.
    Patel PH, Chadalavada RS, Ishill NM et al (2008) Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 26 (abstr. 5008)Google Scholar
  33. 33.
    Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802–811PubMedGoogle Scholar
  34. 34.
    Patard J-J, Fergelot P, Karakiewicz PI et al (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Carncer 123:395–400CrossRefGoogle Scholar
  35. 35.
    Atkins M, Regan M, McDermott D et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714–3721PubMedCrossRefGoogle Scholar
  36. 36.
    Klatte T, Zomorodian N, Kabbinavar FF et al (2007) Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma. J Clin Oncol 25 (abstr. 5112)Google Scholar
  37. 37.
    Signoretti S, Regan M, Atkins M (2008) Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int 101(Suppl 4):31–35PubMedCrossRefGoogle Scholar
  38. 38.
    Choueiri TK, Regan MM, Brick AJ et al (2008) Carbonic anhydrase IX (CAIX) and pathologic features as predictors of outcome in patients with metastatic renal cell carcinoma receiving VEGF-targeted therapy. ASCO Annual Meeting J Clin Oncol 26(Suppl 20):16042Google Scholar
  39. 39.
    Choueiri TK, Vaziri SA, Rini I et al (2007) Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25:5012Google Scholar
  40. 40.
    Fan Y, Borowsky AD, Weiss RH (2003) An antisense oligodeoxynucleotide to p21 (Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2:773Google Scholar
  41. 41.
    Weiss RH (2003) p21 Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4:425Google Scholar
  42. 42.
    Hollen CW, Henthorn J, Koziol JA et al (1992) Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma 8:235–241Google Scholar
  43. 43.
    Donskov F, Von der Maase H (2006) Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24:1997–2005Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Carolina Muriel López
    • 1
  • Emilio Esteban
    • 1
  • Aurora Astudillo
    • 2
  • Pablo Pardo
    • 1
  • Jose Pablo Berros
    • 1
  • Marta Izquierdo
    • 1
  • Guillermo Crespo
    • 1
  • Paula J. Fonseca
    • 1
  • Miguel Sanmamed
    • 1
  • Pablo Martínez-Camblor
    • 3
  1. 1.Department of Medical OncologyHospital Universitario Central de AsturiasOviedoSpain
  2. 2.Department of PathologyHospital Universitario Central de AsturiasOviedoSpain
  3. 3.Department of StatisticsHospital Universitario Central de AsturiasOviedoSpain

Personalised recommendations